Role of serum activity of matrix metalloproteinase-9 in restenosis rate after implantation of drug-eluting stents
Background Despite the popularity of coronary stenting in coronary artery disease (CAD), restenosis remains a challenging clinical problem.We aim to test whether serum level of matrix metalloproteinase (MMP)-9 is associated with the development of in-stent restenosis (ISR) in patients treated with drug-eluting stents (DES).Methods 120 patients who were treated with DES were enrolled into our study.Blood samples for measurement of MMP-9 antigen and activity were taken directly before and 48h after percutaneous coronary intervention (PCI).Restenosis was evaluated at 9-12 months by coronary angiography.
SHI Dong-mei ZHOU Yu-jie LIU Yu-yang HAN Hong-ya
Beijing Anzhen Hospital affiliated to Capital Medical University Beijing Institute of heart and blood vessel diseases
国内会议
北京
英文
209-209
2013-03-20（万方平台首次上网日期，不代表论文的发表时间）